Q1 Earnings Estimate for COYA Issued By HC Wainwright

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for Coya Therapeutics in a research report issued on Monday, May 19th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.50) per share for the quarter. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics' Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.93) EPS.

COYA has been the topic of a number of other research reports. Chardan Capital reissued a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, May 13th. D. Boral Capital reaffirmed a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Tuesday, April 22nd. Finally, Wall Street Zen lowered Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $17.00.

Coya Therapeutics Stock Up 3.3%

NASDAQ:COYA traded up $0.19 during trading hours on Tuesday, reaching $5.90. The company had a trading volume of 12,660 shares, compared to its average volume of 72,712. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24. The firm has a market cap of $98.68 million, a price-to-earnings ratio of -9.08 and a beta of 0.49. The business's 50-day simple moving average is $5.97 and its two-hundred day simple moving average is $6.13.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $257.88 million during the quarter, compared to the consensus estimate of $2.63 million.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Jane Street Group LLC increased its position in shares of Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock worth $169,000 after acquiring an additional 13,176 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new position in Coya Therapeutics during the 1st quarter valued at about $65,000. CM Management LLC boosted its stake in Coya Therapeutics by 25.0% during the 1st quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after purchasing an additional 40,000 shares during the last quarter. Dauntless Investment Group LLC bought a new stake in Coya Therapeutics during the 1st quarter worth approximately $1,083,000. Finally, DME Capital Management LP raised its stake in shares of Coya Therapeutics by 29.2% in the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock worth $9,434,000 after purchasing an additional 372,414 shares during the last quarter. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.